About Tissuemed
Tissuemed is a Healthcare company based in Leeds (United Kingdom) founded in 1985, and was acquired by Becton Dickinson in December 2021. Bioadhesive films are developed to seal leaks in surgical procedures. Tissuemed has raised $12.69 million across 6 funding rounds from investors including Gov.uk, BD and 3i Group. The company has 19 employees. The company was acqui-hired. Its focus areas include Life Sciences, Neurology, Medical Devices and Therapeutic Devices. Its legal entity is TISSUEMED LIMITED.
Company details
Tissuemed develops and markets synthetic, self-adhesive, bioadhesive films to prevent air, blood, CSF and other fluid leaks encountered in surgery. All products incorporate a patented polymer on one side that bonds to tissue surfaces. The other surface is non-adhesive, providing favourable structural characteristics, ease of handling and potentially preventing post-surgical adhesions. TissuePatch films are ultimately resorbable and, reassuringly, based on polymers commonly used in other implants. Flagship product TissuePatchDural is used for prevention of CSF leaks in Neuro and Spinal surgery when the Dura Mater has been breached. Tissuemed has been granted regulatory approval of its TissuePatch range of ultra-thin surgical sealant films by Chinese FDA.
- Headquarters Leeds, United Kingdom
- Employees 19
- Stage Acquired
- SectorsHealthcare
- Emailβ’β’β’β’β’β’β’β’
- Website tissuemed.com
- Social LinkedIn X Facebook
- Acquired by Becton Dickinson (Dec 2021)
- Legal Name Tissuemed Limited
- Date of Incorporation 04 Apr, 1985
- Jurisdiction WEST YORKSHIRE
- Total Equity Funding$12.69M (USD)
in 6 rounds
- Latest Funding Round$52.94K (USD), Grant
Nov 2015
- InvestorsGov.uk
& 5 more
- Employee Count19
- Acquired byBecton Dickinson
(Dec 2021)
Funding Insights of Tissuemed
Tissuemed has successfully raised a total of $12.69M across 6 strategic funding rounds. The most recent funding activity was a Grant round of $52.94 thousand completed in November 2015. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $12.69M
- Total Rounds 6
- Last Round Grant β $52,942
- First Round $3M
(May 1999)
- Investors Count 5
All 6 funding rounds of Tissuemed with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Nov 2015 | $52,942 | Grant | β | β | |
| Jul 2015 | Grant | β | β | ||
| Jun 2015 | Grant | β | β | ||
| May 2002 | $656,415 | Grant | β | β | |
| Aug 2000 | $9.69M | Series B | β | β | |
| May 1999 | $3M | Series A | β | β | β |
6 investors in total: 6 institutional.
Investors in Tissuemed
Tissuemed has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Gov.uk, BD and 3i Group.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government agency and accelerator focusing on innovative startups and SMEs | eicfund.eu | Brussels, Belgium | ||
Private equity firm focused on mid-market businesses | 1945 | 3i.com | London, United Kingdom | |
Global private equity and venture capital investments in B2B Tech & Services companies. | bairdcapital.com | |||
Online government services and information are provided to users. | 1707 | gov.uk | London, United Kingdom | |
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium | |
BD is recognized for providing innovative medical technology solutions. | 1897 | bd.com | Franklin Lakes, United States |
Investor details for Tissuemed
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Tissuemed
4 dated milestones of Tissuemed across 36 years, from founding to its latest funding, stage changes and deals.
- Founded Tissuemed is founded.
- Funding First funding round of $3.0M.
- Funding Latest funding round, Grant, of $53K.
- Exit Acquired by Becton Dickinson.
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track β from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Tissuemed
Complete news archive for Tissuemed
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Tissuemed
Tissuemed was founded in 1985 and raised its 1st funding round 14 years after it was founded.
Tissuemed is headquartered in Leeds, United Kingdom. It is registered at Leeds, England, United Kingdom.
Tissuemed is a funded company, having raised a total of $12.69M across 6 funding rounds to date. The company's 1st funding round was a Series A of $3M, raised on May 1999.
Tissuemed has 19 employees.
Tissuemed develops and markets synthetic, self-adhesive, bioadhesive films to prevent air, blood, CSF and other fluid leaks encountered in surgery. All products incorporate a patented polymer on one side that bonds to tissue surfaces. The other surface is non-adhesive, providing favourable structural characteristics, ease of handling and potentially preventing post-surgical adhesions. TissuePatch films are ultimately resorbable and, reassuringly, based on polymers commonly used in other implants. Flagship product TissuePatchDural is used for prevention of CSF leaks in Neuro and Spinal surgery when the Dura Mater has been breached. Tissuemed has been granted regulatory approval of its TissuePatch range of ultra-thin surgical sealant films by Chinese FDA.
Tissuemed has 6 investors. Key investors include Gov.uk, BD, 3i Group, European Union, and EIC Fund.
Tissuemed operates through Tissuemed Limited.
Yes. Tissuemed was acquired by Becton Dickinson in December 2021.

